HHCP
SPRY icon

Hilton Head Capital Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Hilton Head Capital Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.92K Hold
365
– – ﹤0.01% 734
2026
Q1 		$2.93K Hold
365
– – ﹤0.01% 750
2025
Q4 		$4.25K Buy
+365
New +$3.55K ﹤0.01% 670

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Hilton Head Capital Partners's SPRY Position: Q2 2026 in Review

Hilton Head Capital Partners held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 365 shares worth $2.92K. The position accounts for ﹤0.01% of the portfolio, ranked #734.

Hilton Head Capital Partners first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.25K in Q4 2025. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Hilton Head Capital Partners held 365 shares of ARS Pharmaceuticals worth $2.92K as of Q2 2026.
  • Hilton Head Capital Partners left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Hilton Head Capital Partners's portfolio in Q2 2026, its #734 holding.
  • Hilton Head Capital Partners first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Hilton Head Capital Partners's ARS Pharmaceuticals position peaked at $4.25K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.